Htun Zin Mar, Aldawudi Israa, Katwal Prakash C, Jirjees Srood, Khan Safeera
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Radiology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Cureus. 2020 Jun 20;12(6):e8717. doi: 10.7759/cureus.8717.
Asthma patients have commonly been prescribed inhaled corticosteroids (ICSs) as the first line of control therapy. ICSs are associated with an increased risk of pneumonia in chronic obstructive airway disease (COPD) patients. However, the evidence remains controversial in asthma patients. Several observational studies reported an increased risk of pneumonia; however, COPD patients were not excluded clearly in these studies. In observational studies that excluded COPD patients and in randomized controlled trials, ICS use was not found to be associated with the risk of pneumonia. Hence, COPD patients should be excluded in future studies, and the currently available evidence demonstrates that ICS use is not associated with an increased risk of pneumonia in asthma patients.
哮喘患者通常被处方吸入性糖皮质激素（ICSs）作为控制治疗的一线用药。ICSs与慢性阻塞性气道疾病（COPD）患者发生肺炎的风险增加有关。然而，在哮喘患者中，证据仍存在争议。几项观察性研究报告了肺炎风险增加；然而，这些研究并未明确排除COPD患者。在排除了COPD患者的观察性研究和随机对照试验中，未发现使用ICSs与肺炎风险相关。因此，未来的研究应排除COPD患者，目前可得的证据表明，使用ICSs与哮喘患者发生肺炎的风险增加无关。
